⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198196 | 1.00 | — | — | |
| SCHEMBL4573274 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2523801 | 0.98 | GRIK1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL74586 | 0.98 | GRIK1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL74584 | 0.98 | GRIK1 (0.41) | — | |
| SCHEMBL24732858 | 0.83 | GRIK1 (0.53) | — | |
| SCHEMBL30965308 | 0.83 | GRIK1 (0.53) | — | |
| SCHEMBL8655531 | 0.82 | GRIK1 (0.37) | — | |
| SCHEMBL22109971 | 0.82 | GRIK1 (0.37) | — | |
| SCHEMBL8655715 | 0.82 | GRIK1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226861-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4423096-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118488957-A | Spirotricyclic RIPK1 inhibitors and methods of use thereof | 默沙东有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2009042093-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080027218-A1 | Hydroformylation Process for Pharmaceutical Intermediate | DAUGS EDWARD D | 2008-01-31 | — | — | US | disclosed |
| US-20080027218-A1 | Hydroformylation Process for Pharmaceutical Intermediate | DAUGS EDWARD D | 2008-01-31 | — | — | US | disclosed |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007093014-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |